Advertisement
The five new prescription drugs covered by the National Health InsuranceProgram are produced by third party manufacturers, have proven its marketacceptance and are expected to increase market share substantially. OmeprazoleEnteric-coated Capsule is a drug for the treatment of duodenal ulcer. Theother four drugs are traditional Chinese medicine in capsules, tablets andointment respectfully for the treatment of chronic prostate infection,psoriasis, influenza, and meridian pain.
Advertisement
CEO, Zhongyi Liu, said, "The pharmaceutical market is growing at more than20 percent a year in China according to IMS. We are positioned to capture thisopportunity especially the OTC market opportunities as a result of China'sreform to separate the functions of prescribing and dispensing."
The Company's product pipeline pending final SFDA approval status includesIsosorbide Mononitrate-Sustained Release Tablets for cardiovascular disease,Gliclazide-Controlled Release Tablets for Type 2 diabetes and Laevo-Bambuterofor asthma. Lotus Pharmaceuticals' products under pre-clinical studiescomprise Lovastatin, Verapamil Hydrochloride, and Valsartan-Controlled Releasetablets.
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer ofprescription drugs and a licensed national seller of pharmaceutical items inthe People's Republic of China. Lotus operates through its two controlledentities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical,Ltd. Lotus' current drug development pipeline is focused on the treatment ofcerebro-cardiovascular disease, asthma, and diabetes. Liang Fang sells drugsdirectly and indirectly through its national sales channels to hospitals,clinics and drugs stores in 30 provinces of the PRC.
Safe Harbor Statement
This press release contains "forward-looking statements" within themeaning of the "safe-harbor" provisions of the Private Securities LitigationReform Act of 1995. Forward-looking statements include, without limitation,any statement that may predict, forecast, indicate, or imply future results,performance or achievements, and may contain the words "estimate," "project,""intent," "forecast," "anticipate," "plan," "planning," "expect," "believe,""will likely," "should," "could," "would," "may," or words or expressions ofsimilar meaning. Such statements are not guarantees of future performance andcould cause the actual results of the Company to differ materially from theresults expressed or implied by such statements, including, but not limited to,changes from anticipated levels of sales, future national or regional economicand competitive and regulatory conditions, changes in relationships withcustomers, access to capital, increased costs, difficulties in developing andmarketing new products, marketing existing products, customer acceptance ofexisting and new products, the time to get new drugs approved by the StateFood and Drug Administration and other factors. Additional informationregarding risks can be found in the Company's Annual Report on Form 10K andits prior filings with the SEC. Accordingly, although the Company believesthat the expectations reflected in such forward-looking statements arereasonable, there can be no assurance that such expectations will prove to becorrect. The Company has no obligation to update the forward-lookinginformation contained in this press release.For more information, please contact: Lotus Pharmaceuticals, Inc. Yan ZENG, CFO Tel: +86-10-6389-9868 Email: [email protected]
SOURCE Lotus Pharmaceuticals, Inc.
